% alzhub.org library filter
% Source: https://alzhub.org/research?journal=Expert+opinion+on+biological+therapy
% 8 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{dasilva2026-41671691,
  author  = {da Silva, A. M. P. and de Deus, O. and Januário Campos Cardoso, L. and Virgilio Ribeiro, F. and Froelich Meldola, P. and Rodrigues Menezes, I. and Lee Han, M. and Quiroga, D. G. and others},
  title   = {{Efficacy, safety, and ARIA risk of anti-β-amyloid antibodies in early Alzheimer's disease: a systematic review, meta-analysis, and meta-regression}},
  journal = {Expert opinion on biological therapy},
  year    = {2026},
  doi     = {10.1080/14712598.2026.2631536},
  pmid    = {41671691},
  url     = {https://doi.org/10.1080/14712598.2026.2631536}
}

@article{chhabra2024-39432414,
  author  = {Chhabra, Akanksha and Solanki, Siddhant and Saravanabawan, Prithvi and Venkiteswaran, Arun and Nimmathota, NagaTarang and Modi, Nishi Manojkumar},
  title   = {{A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2024},
  doi     = {10.1080/14712598.2024.2416947},
  pmid    = {39432414},
  url     = {https://doi.org/10.1080/14712598.2024.2416947}
}

@article{doggrell2024-38414336,
  author  = {Doggrell, S. A.},
  title   = {{More failure with solanezumab - this time in preclinical Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2024},
  doi     = {10.1080/14712598.2024.2325551},
  pmid    = {38414336},
  url     = {https://doi.org/10.1080/14712598.2024.2325551}
}

@article{panza2018-29037101,
  author  = {Panza, Francesco and Seripa, Davide and Lozupone, Madia and Solfrizzi, Vincenzo and Imbimbo, Bruno P and Barulli, Maria Rosaria and Tortelli, Rosanna and Capozzo, Rosa and others},
  title   = {{The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset}},
  journal = {Expert opinion on biological therapy},
  year    = {2018},
  doi     = {10.1080/14712598.2018.1389885},
  pmid    = {29037101},
  url     = {https://doi.org/10.1080/14712598.2018.1389885}
}

@article{kerchner2010-20497044,
  author  = {Kerchner, Geoffrey A and Boxer, Adam L},
  title   = {{Bapineuzumab}},
  journal = {Expert opinion on biological therapy},
  year    = {2010},
  doi     = {10.1517/14712598.2010.493872},
  pmid    = {20497044},
  url     = {https://doi.org/10.1517/14712598.2010.493872}
}

@article{samadi2011-21504387,
  author  = {Samadi, H. and Sultzer, D.},
  title   = {{Solanezumab for Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2011},
  doi     = {10.1517/14712598.2011.578573},
  pmid    = {21504387},
  url     = {https://doi.org/10.1517/14712598.2011.578573}
}

@article{tayeb2013-23574434,
  author  = {Tayeb, H. O. and Murray, E. D. and Price, B. H. and Tarazi, F. I.},
  title   = {{Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?}},
  journal = {Expert opinion on biological therapy},
  year    = {2013},
  doi     = {10.1517/14712598.2013.789856},
  pmid    = {23574434},
  url     = {https://doi.org/10.1517/14712598.2013.789856}
}

@article{panza2014-24981190,
  author  = {Panza, F. and Solfrizzi, V. and Imbimbo, B. P. and Logroscino, G.},
  title   = {{Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?}},
  journal = {Expert opinion on biological therapy},
  year    = {2014},
  doi     = {10.1517/14712598.2014.935332},
  pmid    = {24981190},
  url     = {https://doi.org/10.1517/14712598.2014.935332}
}